The relationship between fractional exhaled nitric oxide and asthma symptom scores in patients on mepolizumab
D. Jackson (London, United Kingdom), L. Shackshaft (London, United Kingdom), L. Green (London, United Kingdom), C. Roxas (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), G. D'Ancona (London, United Kingdom), M. Elstad (London, United Kingdom), A. Douiri (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom)
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jackson (London, United Kingdom), L. Shackshaft (London, United Kingdom), L. Green (London, United Kingdom), C. Roxas (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), G. D'Ancona (London, United Kingdom), M. Elstad (London, United Kingdom), A. Douiri (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom). The relationship between fractional exhaled nitric oxide and asthma symptom scores in patients on mepolizumab. 2623
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Usefulness of fractional exhaled nitric oxide (FeNO) for early diagnosis of asthma in patients with nonspecific respiratory symptoms Source: Annual Congress 2009 - From cough to sound analysis of breathing Year: 2009
The relationship between exhaled nitric oxide and compliance/adherence in patients with bronchial asthma using inhaled corticosteroids Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012
Comparisons for concentration in exhaled nitric oxide between patients with bronchial asthma and COPD Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007
Salt chamber treatment had no effect on fractional exhaled nitric oxide (FeNO) in patients with symptoms suggesting asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
In current smokers fraction of exhaled nitric oxide is not associated with asthma symptoms Source: Annual Congress 2010 - Asthma: breath biomarkers and asthma control Year: 2010
Fractional exhaled nitric oxide (FeNO) for an early diagnosis of asthma Source: Eur Respir J 2006; 28: Suppl. 50, 677s Year: 2006
Is exhaled nitric oxide (eNO) an indipendent outcome measure in chronic stable asthma? Source: Eur Respir J 2002; 20: Suppl. 38, 196s Year: 2002
The effect of phosphogliv admission on exhaled nitric oxide level in patients with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 281s Year: 2005
The effect of phosphogliv admission on exhaled nitric oxide level in patients with bronchial asthma Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Using fractional exhaled nitric oxide level to differentiate asthma–COPD overlap syndrome from COPD Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018
The clinical utility of exhaled nitric oxide (eNO) in asthma, the first 1,000 patients Source: Eur Respir J 2004; 24: Suppl. 48, 304s Year: 2004
Exhaled nitric oxide (FeNO) in relation to exacerbation of childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009
Stability of exhaled nitric oxide (FE NO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Clinical usefulness of fractional exhaled nitric oxide (FeNO) as a marker of long-term asthma control Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009
Clinical utility of fractional exhaled nitric oxide in severe asthma management Source: Eur Respir J, 55 (3) 1901633; 10.1183/13993003.01633-2019 Year: 2020
Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Rint, exhaled nitric oxide and the prediction of asthma and respiratory symptoms in children Source: Eur Respir J 2005; 26: Suppl. 49, 479s Year: 2005
The effect of inhaled corticosteroid therapy on exhaled nitric oxide and exhaled hydrogen peroxide in asthma patients Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum Year: 2006
Exercise training and exhaled nitric oxide (eNO) in COPD patients of different severity Source: Eur Respir J 2001; 18: Suppl. 33, 222s Year: 2001
Relationship between fractional exhaled nitric oxide and nasal symptom in allergic rhinitis Source: Annual Congress 2010 - Asthma: breath biomarkers and asthma control Year: 2010